Should You Buy Crocs Inc (CROX) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
82.510
1 Day change
-0.43%
52 Week Range
122.840
Analysis Updated At
2026/01/28
CROX is not a good buy right now for a beginner, long-term investor who wants to act immediately. The stock’s technical trend is bearish (weak momentum and bearish moving averages), fundamentals recently contracted (Q3 2025 revenue/EPS down YoY), and Wall Street sentiment has turned more cautious with multiple downgrades and limited near-term catalysts. I would HOLD/avoid new buying at this moment rather than initiate a position today.
Technical Analysis
Price/Trend: CROX is in a downtrend with bearish alignment in moving averages (SMA_200 > SMA_20 > SMA_5), indicating persistent longer-term downside pressure.
Momentum: MACD histogram is negative (-0.257) and expanding lower, suggesting downside momentum is strengthening rather than stabilizing.
RSI: RSI_6 at ~33.4 is near oversold territory, which can support a short-term bounce, but by itself it is not enough to reverse a broader downtrend.
Levels: Pivot ~83.997. Immediate support S1 ~81.701 (then S2 ~80.283). Resistance levels at ~86.293 (R1) and ~87.711 (R2). With price ~82.86, the stock is sitting just above support; a break below ~81.70 would be technically negative.
Pattern/short-horizon trend model: Similar-pattern projection implies slightly negative drift over the next day/week and more negative bias over the next month (approx. -0.75%).
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Sentiment read: Open interest put-call ratio at 0.67 suggests positioning is more call-heavy overall (mildly bullish/less hedged). However, the option volume put-call ratio at 1.21 shows today’s flow is put-heavier (more near-term caution/hedging).
Volatility: 30D IV ~48.3 vs historical vol ~44.1 (IV moderately elevated), implying the options market is pricing meaningful movement (often seen ahead of events like earnings). Volume vs 30-day average is low (~52.9%), so the bearish volume skew is notable but not on unusually heavy activity.
Technical Summary
Sell
11
Buy
2
Positive Catalysts
Upcoming event: Q4 2025 earnings on 2026-02-12 (pre-market) could act as a catalyst if guidance/revenue trends improve.
Positioning/flows: Hedge funds are reported as buying aggressively (buying amount up ~599.85% QoQ), which can be a supportive medium-term signal.
Potential oversold setup: RSI near oversold and price near support (~81.70) can enable a technical bounce if buyers step in.
Neutral/Negative Catalysts
Political/congress flows: No supportive signal from congress trading data (none available in the last 90 days).
Financial Performance
Latest reported quarter: 2025/Q3.
Growth/profit trend: Revenue fell to ~$996.3M (-6.20% YoY). Net income dropped to ~$145.8M (-27.02% YoY). EPS declined to 2.70 (-19.64% YoY). Gross margin decreased to 58.52% (-1.86% YoY).
Interpretation: Results show contracting demand/profitability versus last year and some margin pressure, which aligns with the cautious near-term narrative from analysts (wholesale caution, tariffs, brand/channel cleanup).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Ratings have become more cautious. Baird downgraded to Neutral (PT $100) on 2026-01-07. KeyBanc downgraded to Sector Weight from Overweight (no PT) on 2026-01-22 citing challenged U.S. demand, tariff headwinds, and Heydude pressure with limited near-term catalysts. Barclays maintained a neutral stance (Equal Weight) while raising PT to $86 after a Q3 beat (2025-10-31). BWG Global moved from Negative to Mixed (2026-01-08), a modest improvement but not a clear bullish endorsement.
Wall Street pros: Some acknowledgment of operational actions/reset progress and potential longer-term brand health improvements.
Wall Street cons: Limited visibility and catalysts near-term, demand pressure (notably U.S.), wholesale caution, tariff headwinds, and ongoing Heydude cleanup pressures.
Wall Street analysts forecast CROX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CROX is 90.38 USD with a low forecast of 75 USD and a high forecast of 112 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast CROX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CROX is 90.38 USD with a low forecast of 75 USD and a high forecast of 112 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
7 Hold
0 Sell
Moderate Buy
Current: 82.870
Low
75
Averages
90.38
High
112
Current: 82.870
Low
75
Averages
90.38
High
112
KeyBanc
Ashley Owens
Overweight -> Sector Weight
downgrade
AI Analysis
2026-01-22
Reason
KeyBanc
Ashley Owens
Price Target
AI Analysis
2026-01-22
downgrade
Overweight -> Sector Weight
Reason
KeyBanc analyst Ashley Owens downgraded Crocs to Sector Weight from Overweight without a price target. The company's U.S. demand remains challenged, the analyst tells investors in a research note. The firm sees limited visibility for Crocs given ongoing wholesale caution, tariff headwinds, and continued pressure at Heydude as the channel cleanup continues. KeyBanc believes the stock has limited catalysts near-term and prefer to remain on the sidelines until the company's compares get easier in the second half of 2026.
BWG Global
Negative
to
Mixed
upgrade
2026-01-08
Reason
BWG Global
Price Target
2026-01-08
upgrade
Negative
to
Mixed
Reason
BWG Global upgraded its view of Crocs to Mixed from Negative, citing checks with buyers, distributors and managers from China and the U.S.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CROX
